Paul Sargos
Radiotherapy — Institut Bergonié, France
Paul Sargos
LeadR Profile
Radiotherapy
Subspecialties: Urology - Oncology - Nuclear Medicine
Main Topics
Publications and Clinical Studies
Profile data updated on
Expert Rankings
Top experts on the MeSH terms this expert works on
Organizations
Career arc: 2010 - 2027
Number : 390
Citations
Main journals
Best Journals
Breakdown by type
Click a legend label to hide or show it in the chart.
Latest Publications
5 most recent indexed articles
Source: Pubmed
| Title | Journal | Year | Citations |
|---|---|---|---|
| High-dose radiotherapy in patients with high-risk prostate cancers treated with long-term androgen deprivation therapy (GETUG AFU 18): a randomised, phase 3 trial. radiotherapy, urinary bladder, progression-free survival, androgens, neoplasms, prostate, prostate-specific antigen, drug-related side effects and adverse reactions, urethra, prostatic neoplasms, therapeutics | Lancet Oncol Top journal | 2026 | 1 |
| Immunological and inflammatory biomarkers of localized and locally advanced prostate cancer treated with radiotherapy. radiotherapy, cells, circulating tumor dna, lymphocytes, neoplasms, prostate, biomarkers, immune system diseases, prostatic neoplasms, precision medicine, therapeutics, tumor microenvironment | Front Immunol | 2026 | 0 |
| Influence of Adverse Pathologic Features on Potential Benefit of Hormone Therapy Use with Postoperative Radiotherapy in Recurrent Prostate Cancer: An Individual Patient Data Meta-analysis. radiotherapy, margins of excision, urology, neoplasms, prostate, hormones, prostatic neoplasms, therapeutics, seminal vesicles | Eur Urol | 2026 | 1 |
| Evidence Thresholds for Novel Therapeutic Strategies in Prostate Cancer: A Consensus Statement from the Prostate Cancer Committee of the French Urological Association. neoplasms, prostate, prostatic neoplasms, therapeutics | Fr J Urol | 2026 | 0 |
| Temozolomide Versus Radiotherapy as First-Line Therapy for Low-Grade Glioma: Mature Results of a Randomized Phase III Trial (EORTC 22033-26033/NCIC-CTG/TROG/MRC-CTU). radiotherapy, glioma, progression-free survival, temozolomide, astrocytoma, neoplasms, therapeutics | J Clin Oncol Top journal | 2026 | 4 |
Clinical Studies 18
Synthesis
By phase:
By status:
By type:
By Monocentric/Multicentric:
Ongoing Clinical Trials
3 ongoing trials started since 2021, where this expert is an investigator
Source: ClinicalTrials
| Study | Phase | Status | Start |
|---|---|---|---|
| Treatment with darolutamide radiation therapy for patients with a castration resistant cancer and metastases detected by functional imaging 2023-507482-26-00 — radiotherapy, choline, radiosurgery, tomography, positron-emission tomography, neoplasms, prostate, neoplasm metastasis, prostatic neoplasms, castration, therapeutics | Phase 3 | Recruiting | 2024 |
| Evaluation of the Stereotactic MR guided Adaptive Radiotherapy for Locally Advanced Pancreatic Cancers NCT07097064 — radiotherapy, pancreatic neoplasms, neoplasms, adenocarcinoma, radiotherapy, conformal, drug therapy, chemotherapy | Phase 2 | Not yet recruiting | 2025 |
| Randomized Phase II Trial on Short Term Darolutamide Concomitant to Radiation Therapy for Patients With Intermediate Unfavorable Risk Prostate Cancer NCT05346848 — radiotherapy, injections, gonadotropin-releasing hormone, androgens, neoplasms, prostate, aftercare, prostatic neoplasms, therapeutics | Phase 2 | Recruiting | 2023 |
LeadR Networks
Main global connection map